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and §Mathematical Biosciences Institute, The Ohio State University, Columbus, OhioABSTRACT A kinetic model of a molecular control system for the cellular decision to proliferate or differentiate is formulated
and analyzed for the purpose of understanding how the system can break down in cancer cells. The proposed core of this control
system is composed of the transcription factors Myc and p53. The network of interactions between these factors involves nega-
tive and positive feedback loops that are linked to pathways involved in differentiation, cell cycle, and apoptosis. Understanding
the dynamics of the Myc-p53 control system is aided by the postulate that there exists a cancer zone defined as a range of onco-
genic Myc activities where the probability of initiating cancer is high. We propose that an essential role of p53 is to prevent the
system from entering or staying too long in the cancer zone by downregulating Myc or, when Myc activity somehow becomes too
high, by inducing apoptosis, cell cycle arrest, or differentiation. Kinetic modeling illustrates how deletions or aberrations in PTEN,
MDM2, and ARF (genes implicated in various cancers, including glioma) affect the Myc-p53 control system. In addition,
computer simulations demonstrate how this control system generates different cellular phenotypes characterized by rates of
cellular differentiation and proliferation.INTRODUCTIONSeveral studies point to the proto-oncogene c-Myc and the
tumor suppressor gene p53 as key players in the control of
stem or progenitor cell proliferation and differentiation
(1,2). Perturbations in the function of either of these proteins
could lead to increased cell proliferation without concomi-
tant differentiation, resulting in a continuous supply of
stem cells with tumorigenic potential (3–6). For example,
deletion of p53 and PTEN in mouse neural stem cells gives
rise to poorly differentiating cells with increased Myc
protein levels and high proliferation rates, resulting in
malignant tumors that resemble glioblastomas (7–9). In
this article, we attempt to integrate and organize the Myc-
p53 interactions to reveal how they coordinate cell prolifer-
ation and differentiation. We then propose and analyze a
modular qualitative network model to predict cellular
phenotypes characterized by degrees of differentiation, rates
of proliferation and apoptosis; and we identify six pheno-
types at this level of network resolution.
Myc and p53 affect cell differentiation and proliferation
in opposite but nonindependent ways (see details in Table
S1 in the Supporting Material). We highlight the fact that
Myc and p53 interact through negative and positive feed-
back loops, and predicting their influence on cell prolifera-
tion and differentiation is not straightforward. We therefore
formulate kinetic models to aid our understanding of the
dynamics of the network. These mathematical models are
phenomenological in nature because we are only represent-Submitted August 3, 2011, and accepted for publication September 30,
2011.
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0006-3495/11/11/2082/10 $2.00ing the qualitative trend of how a change in the activity of
a protein in the network affects its targets.
We illustrate how to find effective control parameters
associated with the Myc-p53 feedback loops and demon-
strate how perturbations of these parameters affect Myc
levels. Some of these perturbations could induce Myc to
enter a cancer zone (CZ) where a range of Myc levels gives
significant probability of cancer initiation (the CZ postulate
is described in more detail in the next section). We discuss
how some of the Myc-p53 interactions may also be accom-
plished through indirect pathways and, as a specific ex-
ample, illustrate how two of the major signaling pathways
compromised in gliomas (PTEN/AKT and ARF/MDM2
pathways) are linked to the core Myc-p53 control system.
Finally, we demonstrate by kinetic simulations how dif-
ferent cell phenotypes are generated by signaling pathways
to the Myc-p53 system that controls the downstream path-
ways involved in cell proliferation and differentiation.METHODS
The PubMed literature database (http://pubmed.org) was searched for
genetic, biochemical, and other molecular interactions involving Myc and
p53, and for their influence on proliferation and differentiation of mamma-
lian cells (human, mouse and rat). These interactions are summarized in
Fig. 1 a. The qualitative interactions (arrow and hammerhead) are either
direct or indirect, and are given the following kinetic interpretation: X/
Y means increase in X leads to a positive rate of change of Y, and X–jY
means increase in X leads to a negative rate of change in Y (see Aguda
and Goryachev (10) for more discussion of this interpretation). Table S1
lists specific interactions and literature references for the interactions de-
picted in Fig. 1 a.
As indicated in the Cell Proliferation Module in Fig. 1 a, proliferation is
determined by the net activities of cell cycle factors (PC) and apoptosisdoi: 10.1016/j.bpj.2011.09.052
FIGURE 1 (a) A qualitative network involving Myc and p53 in the
control of cell proliferation and differentiation. (Arrows) Activation or up-
regulation. (Hammerheads) Inhibition or downregulation. Table S1 in the
Supporting Material lists references supporting interactions 1–11. Abbrevi-
ations: sTF, stemness transcription factors; dTF, transcription factors
inducing differentiation; PC, cell cycle factors; PA, apoptosis factors. (b)
As Myc activity increases, a cell transitions from quiescence to the cell
cycle, and eventually to apoptosis. The cancer zone is postulated to exist
between normal cell cycle and apoptosis.
Myc-p53 Control System 2083factors (PA). Similarly, as shown in the Differentiation Module, cell differ-
entiation occurs when the activities of differentiation transcription factors
(dTF) dominate those of stemness transcription factors (sTF). Examples
of sTF are the pluripotency factors Oct4, Sox2, and Nanog (11,12). Exam-
ples of dTF are transcription regulators such as GATA6 and CDX2 that
induce the endoderm and trophectoderm lineages, respectively (13).
Cellular phenotypes are characterized according to the relative activities
of the four submodules PC, PA, sTF, and dTF. Kinetic modeling of the
detailed networks of these submodules are interesting problems in their
own right (13–17), but will not be considered in detail here.
We refer to the interactions represented by edges 1–3 in Fig. 1 a as the
core Myc-p53 control system. The dynamics of this system is modeled
by a system of ordinary differential equations according to the aforemen-
tioned kinetic interpretation of arrows and hammerheads in the model
network. These equations are then recast into dimensionless forms to
reduce the number of parameters and determine the effective control param-
eters. The control parameters associated with the feedback loops between
Myc and p53 are perturbed to investigate the sensitivity of Myc on these
parameters. To interpret the significance of the magnitudes of the changes
in Myc, we invoke the existence of a cancer zone (CZ) defined as a range of
Myc activities wherein the probabilities of initiating cancer are high. The
CZ postulate was first proposed by Aguda et al. (18) and is in strong accord
with the experimental observations in vivo (e.g., see Murphy et al. (19) and
Aguda and Algar (14)). As illustrated in Fig. 1 b, a cell transitions through
states of quiescence, cell cycling, and apoptosis as Myc activity increases;
in between cell cycling and apoptosis is the postulated CZ.
Myc and p53 are coupled to two of the major deregulated signaling path-
ways involved in gliomagenesis, namely, the ARF/MDM2 and PTEN/AKT
pathways (20). The Myc-p53 network is extended with simplified versions
of these pathways, and a correspondingly extended system of dimensionless
differential equations is used to describe the dynamics of the composite
network. Because they are common perturbations in gliomas, the effects
of deleting the genes PTEN and ARF, and the overexpression of MDM2,
on the levels of Myc are simulated.
The final set of model differential equations studied in this article
involves the core Myc-p53 control system and signaling pathways to the
Differentiation Module and Proliferation Module (these modules’ compo-nents are shown in Fig. 1 a). To illustrate how various cellular phenotypes
are generated by this modular network, we varied the strengths of two
signaling pathways, one to Myc and the other to dTF.
All model differential equations are computationally integrated using
routine ode23 in MATLAB (The MathWorks, Natick, MA). Values of
dimensionless parameters are estimated from published experimental
values where available. For example, the following values of protein
half-lives (t1/2) are used: Myc, ~20–30 min (21); p53, ~15 min (22);
Mdm2, ~30 min (23); Pten, >12 h (24); and ARF, ~6 h (25). A first-order
protein decay coefficient (d) is related to the half-life by the formula d ¼
(ln 2)/t1/2. Dimensionless kinetic equations generally require only knowl-
edge of ratios of parameters (i.e., not their absolute values). The arbitrarily
assigned values for some of the dimensionless parameters in our simula-
tions may be considered as predictions on the ratios of the absolute values
of corresponding parameters that generate the dynamic behavior exhibited
by the models.RESULTS AND DISCUSSION
Failsafe mechanisms of the Myc-p53 control
system and possible cell phenotypes
When proliferative signals increase Myc activity, cells are
induced to enter the cell cycle as indicated by edge 8 in
Fig. 1 a. Increases in Myc are attenuated by the negative
feedback loop composed of edges 1 and 2. If this attenuation
fails and Myc increases out of control, several failsafe
mechanisms are available to negate Myc’s oncogenic poten-
tial. These mechanisms include p53-dependent (edges 2
and 9) and p53-independent (edge 10) cell death via
apoptosis, p53-dependent cell cycle arrest (edge 11), and
p53-induced cell differentiation (edges 5 and 7). Which of
these failsafe mechanisms are operative would depend on
the parameters and initial conditions of the system. Note
that edge 3 forms a loop of mutual repression between
Myc and p53 (a positive feedback loop) that compromises
the aforementioned p53-mediated failsafe mechanisms.
A qualitative analysis of the modular model in Fig. 1
a suggests how various cellular phenotypes can be gener-
ated. Let the right superscripts ‘‘þ’’ and ‘‘’’ on a submod-
ule mean ‘‘on’’ and ‘‘off,’’ respectively. Inside the
Differentiation Module, two combinations of the submodule
states are probable, namely, [sTF]þ[dTF] and
[sTF][dTF]þ, because of the mutual antagonism between
sTF and dTF. Let Dþ ¼ [sTF][dTF]þ and D ¼
[sTF]þ[dTF] represent differentiating and undifferentiated
cells, respectively. Inside the Proliferation Module, three
combinations of the submodule states are possible, namely,
CþA, CAþ, and CA, where C and A are associated
with the PC and PA submodules, respectively, as shown in
Fig. 1 a. There are six possible submodule combinations
and phenotypes as listed in the first and second columns,
respectively, of Table 1. The third column lists the possible
values of Myc, namely, mQ (set of values of Myc for quies-
cent cells), mC (set of values of Myc for cells in the cell
cycle), mCZ (set of values of Myc for cells in the cancer
zone), and mA (set of values of Myc for cells undergoing
apoptosis).Biophysical Journal 101(9) 2082–2091
TABLE 1 Six cellular phenotypes and corresponding qualitative values of Myc
Submodule combinations Cellular phenotypes Values of Myc (m)
DþCþA Differentiating proliferating cells (cancer transit-amplifying
cells possible)
m ˛ {mC, mCZ}
DþCAþ Dying differentiated quiescent cells m ˛ mA
DþCA Differentiated quiescent cells m ˛ mQ or m ˛ {mC, mCZ} but cell-cycle arrested cells
DCþA Undifferentiated dividing cells (cancer-stem-like cells possible) m ˛ {mC, mCZ}
DCAþ Dying undifferentiated quiescent cells (dying normal stem cells) m ˛ mA
DCA Undifferentiated quiescent cells (normal stem cells) m ˛ mQ or m ˛ {mC, mCZ} but cell-cycle arrested cells
2084 Aguda et al.Controlling the feedback loops between Myc
and p53
The core Myc-p53 network and its associated generalized
dynamical equations are shown in Fig. 2. Signaling path-
ways to Myc and p53 are indicated by s1 and s2, respec-
tively, and protein degradation pathways are shown with
rate coefficients dm and dp. By nondimensionalizing the
equations, we show here that the parameters of the network
can be lumped into a fewer number of effective control
parameters.
The variables m and p in the phenomenological equations
in Fig. 2 b are protein activities of Myc and p53, respec-
tively. As indicated in the b1 equation in the figure, the
signal s1 increases the rate of Myc activation through the
function f(s1), whereas p53-dependent inhibition of Myc is
through the function F(p) in the denominator. A requirement
on these functions is that vf/vs1R 0 for all nonnegative s1,
and vF/vpR 0 for all nonnegative p. Similarly, the second
term on the right-hand side of the b2 equation in the figure
represents the increase in p53 activity induced by signal s2,
and Myc-dependent suppression of p53 activity through the
function H(m) in the denominator. Myc-dependent increase
in p53 activity is represented by the function g(m). One must
also have vH/vmR 0 and vg/vmR 0 for all nonnegative m.
Consider a simple case where f(s1) ¼ s1, g(m) ¼ m,
h(s2) ¼ s2, F(p) ¼ p, and H(m) ¼ m so that the dynamical
equations are
dm
dt
¼ ε1s1
k1 þ p dmm; (1)FIGURE 2 (a) The Myc-p53 core control system, and its (b) generalized
phenomenological dynamical equations. See text for details.
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dt
¼ k2mþ
k3 þ m dpp: (2)
These equations can be recast in dimensionless forms as
follows:
dm
dt
¼ 1
k01 þ s02 p
 m; (3)
0 dp

0  1 d
dt
¼ k2m þ k03 þ s01m
 p ; (4)
where
t ¼ dmt; m ¼ m
s1
; p ¼ p
s2
; (5)
0 dm 0 s1 0 dpk1 ¼ ε1 k1; k2 ¼ s2dp k2; k3 ¼ ε2 k3; (6)
0 dp 0 dm 0 dms1 ¼ ε2 s1; s2 ¼ ε1 s2; d ¼ dp : (7)
The dimensionless parameters in Eqs. 3 and 4 are referred to
as effective control parameters. For example, the strength of
the inhibition of Myc by p53 can be controlled through the
dimensionless parameter s2
0 that, according to the middle
expression in Eq. 7, is directly proportional to the parameter
of the signaling pathway to p53 (s2), directly proportional to
the parameter for the degradation of Myc (dm), and inversely
proportional to the coefficient of signaling to Myc (ε1).
Varying the parameters s2, dm, and ε1 in different ways but
keeping the same value of s2
0 will generate qualitatively
identical behaviors. To represent a mutation in p53 that
would decrease its ability to downregulate Myc activity,
one could decrease the value of k1
0 or s20. For instance,
a deletion of p53—corresponding to setting s2
0 to 0—could
explain the observed increased Myc levels in neural stem
cells of p53-knockout mice (7). Another interesting example
of an effective control parameter is k2
0, which is associated
with Myc-dependent activation of p53. According to the
middle expression in Eq. 6, to increase k2
0, one can increase
Myc-p53 Control System 2085either k2 or s1, or decrease s2 (signal to p53) or the degrada-
tion rate of p53 (dp).
Computer simulations using Eqs. 3 and 4 are shown in
Fig. 3. Due to the negative feedback between Myc and
p53, and with the chosen initial conditions (given in the
legend of Fig. 3 a), Myc spikes and decreases as p53 builds
up. For illustrative purposes only, the cancer zone (CZ) is
arbitrarily represented by the shaded band in Fig. 3 (between
m* ¼ 3 and m* ¼ 4.5). We propose that the amount of time
spent inside the CZ (as indicated by the dark-shaded area,
ACZ, in Fig. 3 a) is a key determinant of the probability of
initiating carcinogenesis. The larger the ACZ, the greater
this probability. Note that even if Myc enters CZ, the prob-
ability could be negligible if the time spent in CZ is insignif-
icant. Long-term elevated levels of Myc within CZ, as
exemplified by Fig. 3, c and d, give rise to significant prob-
abilities of initiation of cancer.
In the simulations shown in Fig. 3, b–d, we illustrate how
Myc enters or exits CZ when the strength of the negative
feedback loop between Myc and p53 varies—e.g., as the
values of k2
0 or s20 change. Increasing either k20 or s20 lowers
Myc long-term (steady state) activity, thereby pushing the
system below the CZ (Fig. 3, b and c). In contrast, increasing
s1
0 strengthens the positive feedback loop between Myc and
p53, driving entry into the CZ. Note that the values of k2
0
and s1
0 relative to each other determine whether the negative
feedback between Myc and p53 (edges 1 and 2 in Fig. 1 a) is
stronger or weaker than the positive feedback between these
factors (edges 1 and 3). Increasing s1
0 and decreasing s20
favors Myc in its battle against p53. When manipulatingFIGURE 3 Myc and p53 activities as functions of time according to
Eqs. 3 and 4. (a) Activities of Myc (m*) and p53 (p*) versus time. For illus-
trative purposes only, a cancer zone (CZ) is arbitrarily indicated by the gray
band between m*¼ 3 and 4.5. (b) Myc versus time, for varying k20. (c) Myc
versus time, for varying s2
0. (d) Myc versus time, for varying s1
0
. Parameter
values: k1
0 ¼ 0.01, k20 ¼ 0.1 (varies in b), k30 ¼ 0.01, s10 ¼ 1 (varies in d),
s2
0 ¼1 (varies in c), d0 ¼ 0.5. Initial conditions: m*(0) ¼ 0.1, p*(0) ¼ 0.05.the parameters k2
0, s20, and s10, we emphasize that the
expressions of the dimensionless parameters in Eqs. 6 and
7 provide key information on what parameters can be
controlled experimentally.
A detailed analysis of the stability of the steady states of
the core Myc-p53 system (Eqs. 3 and 4) is provided in the
second part of the Supporting Material. We show that there
is at most one nonnegative steady state of the system for
every set of positive parameters and, importantly, a rapid
increase in the steady state of Myc (ms*) at a bifurcation
point where an instability emerges. This bifurcation point
is shown in Fig. 4. The bifurcation diagram looks like a
pitchfork, but broken into two pieces. The parameter s1
0 is
the parameter associated with edge 3 in Fig. 1 a and is a
parameter that can control the strength of the positive feed-
back loop (mutual antagonism) between Myc and p53. The
bifurcation point is located at s1
0 ~ 0.9, corresponding to the
point where the dashed curve (unstable steady states) and
the solid curve (stable steady states) merge in Fig. 4. Note
that the lower broken piece of the pitchfork is in the negative
region (shaded area). Although the saddle-node bifurcation
value of ms* is located in the negative region, this bifurca-
tion phenomenon is manifested in the rapid increase in the
positive ms* immediately to the right of the bifurcation
point. Details in the derivation of the exact conditions on
the parameters for instability to occur, including the inter-
play between stabilizing and destabilizing loops in the
network, are given in the second part of the Supporting
Material. The main result is the following: an instability
arises when
Cþ2 >C
m
1C
p
1 þ C2 (8)FIGURE 4 Steady state of Myc (ms*, dimensionless) versus s1
0 deter-
mined from Eqs. 3 and 4. The parameter s1
0 is associated with edge 3 in
Fig. 1 a. Negative steady states (lower curve, both solid and dashed
portions) are in the shaded region, and are unphysical. (Solid curves) Stable
steady states; (dashed curve) unstable steady states. Parameter values: k1
0 ¼
0.01, k2
0 ¼ 1, k30 ¼ 0.01, s20 ¼ 1, and s10 varies through the range of the
abscissa in this figure.
Biophysical Journal 101(9) 2082–2091
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Cþ2 ¼ s01
s02m
2
s 2;d0 k03 þ s01ms
C2 ¼ k02
s02m
2
s
d0
;
Cm1 ¼ 1 and Cp1 ¼
1
d0
:
(9)
C2
þ is a measure of the strength of the positive feedback
loop (edges 1 and 3 in Fig. 1 a), C2
 is that of the negative
feedback loop (edges 1 and 2), and C1
m and C1
p are the one-
cycles associated with the first-order decay of Myc and p53,
respectively. Lastly, we also prove that Eqs. 3 and 4 do not
give rise to periodic oscillations for all sets of positive
parameters.Perturbations of the Myc-p53 control system
by PTEN, MDM2, and ARF
PTEN is a tumor suppressor gene deleted in many human
cancers, including 70% of human glioblastomas (26–29).
Simultaneous inactivation of p53 and PTEN in mice gives
rise to undifferentiated cells with high proliferative rates
and increased Myc protein levels (7). Furthermore, knock-
ing out p53 and PTEN in mouse neural stem cells is suffi-
cient to produce infiltrative gliomas (8).
The qualitative network shown in Fig. 5 a summarizes
the mutually antagonistic pathways between p53 and Akt
(30–32). This mutual inhibition has been proposed as a
potential switching mechanism for the cellular decision to
survive or die (31,33). Akt is a survival factor because it up-
regulates pathways inhibiting apoptosis and pathways
inducing the cell cycle, whereas p53 promotes apoptosis
and suppresses the cell cycle.
One could discern from Fig. 5 a several reasons why
PTEN deletion has a significant impact on p53 activity:FIGURE 5 (a) Mutual antagonism between {p53, PTEN} and {AKT,
MDM2}. (Arrows) Activation or upregulation. (Hammerheads) Inhibition
or downregulation. (b) The Myc-p53 control system (edges 1–3) and its
interactions with Pten, Mdm2, and Arf. Signaling pathways and degrada-
tion reactions are not shown.
Biophysical Journal 101(9) 2082–2091First, PTEN helps p53 suppress the cell cycle via the
pathway {p53 / PTEN–jAKT / cell cycle}; in other
words, loss of PTEN means cutting off the control of p53
in suppressing cell proliferation via this pathway. Second,
due to the pathway {PTEN–jAKT / MDM2–jp53}, loss
of PTEN implies increased MDM2-induced degradation of
p53. This is why PTEN has been described as protective
of p53 (34). Third, as depicted by the arrow from PTEN
to p53 in Fig. 5 a, PTEN increases p53 stability through
phosphatase-independent mechanisms (35,36).
As shown in Fig. 5 b, pathways involving Mdm2 and Arf
also impinge on the Myc-p53 control system. Mdm2 is an
oncogene frequently overexpressed in human primary glio-
blastomas (27,37). Mdm2 protein possesses ubiquitin ligase
activity that induces degradation of p53 (38) whereas, at the
transcriptional level, p53 promotes expression of Mdm2—
thus, forming a negative feedback loop between these two
proteins (39).
The INK4A/ARF locus is frequently deleted in human
gliomas (27). Uhrbom et al. (40) first reported that loss of
ARF in combination with KRas signaling generate glioma-
blastomas in mice. More recently, Robinson et al. (41)
demonstrated that a combination of activated MEK (a
member of the map kinase pathway) with either activated
Akt or loss of Ink4a/Arf is sufficient to transform mouse
neural progenitor cells into gliomas in vivo. Zindy et al.
(42) first showed that Myc signals through Arf to regulate
p53-dependent apoptosis, and later gave evidence that this
Arf-Mdm2-p53 tumor suppressor pathway is inactivated
in certain cancers (43). As represented by edge 19 in
Fig. 5 b, the inhibition of Arf transcription by p53 (44) com-
pletes a negative feedback loop between Arf and p53 along
with edges 18 and 12. In terms of coordinating self-renewal
and differentiation of mouse neural stem cells, Nagao et al.
(2) observed that low levels of Arf expression promotes
stem cell self-renewal, whereas overexpression of Arf
induces precocious differentiation (in this case, gliogene-
sis)—consistent with the effects mediated by edges 18 and
12 of Fig. 5 b on the Arf-Mdm2-p53 pathway.
To simplify the mathematical model, we collapsed the
pathway {PTEN–j AKT/MDM2} into a single interaction
between PTEN and MDM2 (edge 17 in Fig. 5 b). The
dynamics of this network can be described by the following
set of equations (Fig. 5 b gives the meaning of the letters
m, p, w, q, and v):
dm
dt
¼ ε1s1
k1 þ p dmm; (10)
dp ε2s2
dt
¼ k2mþ k14qþ
k3 þ mþ k12w dpp; (11)
dw ε4s4
dt
¼ k16pþ
k17 þ qþ k18v dww; (12)
Myc-p53 Control System 2087dqdt
¼ ε3s3 þ k13p dqq; (13)
dv k15mdt
¼ ε5s5 þ
k19 þ p dvv: (14)
Note that the indirect effect of Akt signaling is represented
by the parameter s4 in Eq. 12. The dimensionless equations
corresponding to Eqs. 10–14 are given by Eqs. A1–A5, with
dimensionless parameters in Eqs. A6–A10, in the Appendix.
Using Eqs. A1–A5, the effects on Myc of perturbing Pten,
Arf, and Mdm2 are shown in Fig. 6. Deletion of Pten and/or
Arf, as well as overexpression of Mdm2, increases the Myc
steady state. The perturbations of the parameters s3
0, s40, and
s5
0 (Fig. 6) may also be interpreted as perturbations of
signaling pathways impinging on Pten, Mdm2, and Arf,
respectively (see dimensionless parameters in Eqs. A6–
A10). The magnitudes of the increases in the steady state
of Myc will be critical in deciding whether or not the system
enters the CZ. Although experimentally measured rate
parameters are not available at this time, some of the poten-
tial dynamics of the network can be predicted based on the
presence of feedback loops in the network structure. The
negative feedback loop between p53 and Mdm2 has been
predicted—and later validated experimentally—to give
rise to oscillations (33,45). Another negative feedback
loop with potential to cause oscillations is formed between
Arf and p53 through edges 19, 18, and 12 in Fig. 5 b,
although no report of observation of such oscillations has
been published so far. Finally, as already mentioned above
(Fig. 5 a), the mutual antagonism between {p53, Pten}
and {Akt, Mdm2} has been previously modeled and pre-
dicted to generate bistable switching behavior—i.e., an
all-or-none switch between p53 and Akt (31).Coordination of cell differentiation
and proliferation by signaling pathways
To demonstrate how the various cell phenotypes (column 1
of Table 1) are generated, we formulate a dynamical modelMdm2 (by increasing s4
0
from 0 to 1) increases the steady state of Myc. Initia
0.01. Other parameter values and initial conditions are listed at the bottom of t
of Myc. Initial q*(0) ¼ 0.05. Parameters: s50 ¼ 0 and 1, s40 ¼ 0.5, s30 ¼ 1, and
Other parameter values: k1
0 ¼ 0.01, k20 ¼ 0.1, k30 ¼ 0.01, k130 ¼ 0.01, k150 ¼ 0.0
d0 ¼ 0.5, d00¼ 1, d00 0 ¼ 30, and d00 00 ¼ 12. Other initial conditions: m*(0) ¼ 2.5that uses Eqs. 3 and 4 for the core Myc-p53 control system,
and additional equations for the submodules of cell differen-
tiation and proliferation. We assume that there is a particular
marker for sTF, dTF, PC, and PA, with the following symbols
used for their activities: [sTF marker]¼ Ds, [dTF marker]¼
Dd, [PC] ¼ Pc, and [PA] ¼ Pa. We further assume that these
markers possess specific threshold values for becoming
active in driving their corresponding cellular processes;
for example, when Dd surpasses a threshold qd, differentia-
tion occurs. The additional equations are as follows:
dDs
dt
¼ εsss þ ðk6 þ k6bmÞD
4
s
q4s þ D4s þ k5pþ k5bDd
 dsDs; (15)
dDd ðk7 þ k7bpÞD4
dt
¼ εdsd þ d
q4d þ D4d þ k4mþ k4bDs
 ddDd; (16)
dPc ðk8 þ k8bmÞP2c
dt
¼ εcsc þ
q2c þ P2c þ k11p
 dcPc; (17)
dPa ðk10 þ k10bmþ k9pÞP2
dt
¼ εasa þ a
q2a þ P2a
 daPa: (18)
The exponents for Ds, Dd, Pc, and Pa are used to represent
sigmoidal threshold kinetics where the thresholds are given
by the q-values in the denominators (the exponents for Ds
and Dd are arbitrarily assumed larger than those of Pc and
Pa because of the mutual repression of sTF and dTF
factors—as depicted in Fig. 1 a—that may generate sharper
switching behavior than that of proliferation or apoptosis).
The dimensionless versions of Eqs. 15–18 are given by
Eqs. A11–A14, with dimensionless parameters in Eqs.
A15–A20, in the Appendix.
The strengths of signaling pathways are represented by
six parameters, namely, s1
0, s20, ss0, sd0, sc0, and sa0 (these
are the dimensionless parameters given in Eq. A19 in the
Appendix). We study how two of these signaling path-
ways—namely, s1
0 and sd0—coordinate cell proliferationFIGURE 6 Increases in the steady state of Myc
by deletion of Pten, overexpression of Mdm2,
and deletion of Arf. Dimensionless Eqs. A1–A5
and parameter Eqs. A6–A10 in the Appendix are
used in these simulations. (a) Deleting Pten (by
setting k14
0 ¼ s30 ¼ 0) increases the steady state
of Myc. Initial q*(0) ¼ 0. Parameters: s30 ¼ 0
and 1, s4
0 ¼ 0.5, s50 ¼ 0.5, and k140 ¼ 0. Other
parameter values and initial conditions are listed
at the bottom of this caption. (b) Overexpressing
l q*(0) ¼ 0.05. Parameters: s40 ¼ 0 and 1, s30 ¼ 1, s50 ¼ 0.5, and k140 ¼
his caption. (c) Deleting Arf (by setting s5
0 ¼ 0) increases the steady state
k14
0 ¼ 0.01. Other parameter values and initial conditions are listed below.
2, k16
0 ¼ 0.02, k170 ¼ 0.01, k190 ¼ 0.01, s10 ¼ 1, s20 ¼ 1, e30 ¼ 0.1, e50 ¼ 0.1,
, p*(0) ¼ 0.1, w*(0) ¼ 0.03, and v*(0) ¼ 0.05.
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(associated with the parameter s1
0) are activated for cells to
enter the cell cycle or to promote pluripotency. An example
is LIF signaling, which is important in maintaining expres-
sion ofMyc in mouse embryonic stem cells (46), and another
is Wnt signaling (47,48). Signaling pathways that induce
differentiation are represented collectively by sd
0. An
example is signaling to GATA-6 (49), an endoderm master
gene regulator repressed by both Myc and Nanog (50,51).
We explored the effects of varying s1
0 and sd0 to demon-
strate how the phenotypes listed in Table 1 can be generated
by the model equations. Only four of the six phenotypes are
simulated because we do not consider phenotypes with Aþ
(i.e., we ignore dying cells). Equations 3 and 4 and A11–
A14 are integrated until all the variables reach their steady
states. Increasing sd
0 leads to a switch to the Dþ phenotype,
with fixed low s1
0 values (associated with low Myc steady
states) giving rise to terminally differentiated cells (DþC
in Fig. 7 a) and relatively higher values of s1
0 (associated
with high Myc steady states) to transit-amplifying cells
(DþCþ in Fig. 7 c). On the other hand, for fixed values of
sd
0, increasing s10 (associated with increasing Myc steady
states) de-differentiate cells into the cancer stemlike pheno-
type (DCþ in Fig. 7 b).
This DCþ phenotype can be induced to differentiate,
i.e., as transit-amplifying cells (DþCþ), by increasing sd0
as shown in Fig. 7 c. In Fig. 7 d, we show the locations of
these four phenotypes on a phase diagram with coordinates
s1
0 and sd0. This is a low-resolution phase diagram because
we arbitrarily assigned high thresholds for the steady states
Dd*
s (to distinguishDþ fromD) andPc*
s (to distinguish CþBiophysical Journal 101(9) 2082–2091from C). As illustrated in Fig. 7 d, there are regions where
different phenotypes can be generated despite all the model
parameters being fixed. For example, the shaded area with
corners a, b, c, and d in Fig. 7 d switches from DþC to
DþCþ if the initial conditions for Dd* and Pc* are increased
(the figure caption gives values of this change); concomi-
tantly, the darker-shaded area with corners b, c, e, and f in
Fig. 7 d switches from DC to DCþ. Thus, both the
strengths of the signaling pathways (s1
0 and sd0) and the
initial conditions of the system are important in deciding
which phenotype is obtained.CONCLUSIONS
Two recent census of human cancer genes list Myc and p53
in the top groups of frequently amplified and mutated genes,
respectively (52,53). As transcription factors, Myc has been
estimated to bind 10–15% of all gene promoters in the
human genome (54,55), and, for p53, nearly 5000 genes
have at least one p53 consensus binding sequence in their
promoter regions (56,57). It is therefore not surprising that
these factors have been shown in many instances to play
key roles in stem/progenitor cell proliferation and differen-
tiation. We have reviewed the literature and summarized the
evidence showing that Myc and p53 exert opposite effects
on these cellular processes (Fig. 1 a and see Table S1).
Because proliferation and differentiation are not indepen-
dent processes in a developing organism, we expect that
Myc and p53 must talk to each other. Indeed, such a bidirec-
tional communication exists as illustrated by the negative
feedback loop between edges 1 and 2 in Fig. 1 a.FIGURE 7 Steady states Dd*
s, Pc*
s, and m*s
versus signaling parameters s1
0 and sd0 (a) for
varying sd
0 with s10 ¼ 1, (b) for varying s10 with
sd
0 ¼ 1, and (c) for varying sd0 with s10 ¼ 8. (d)
Phase diagram showing the location of the pheno-
types, with Dþ assigned for Dd*
s R 10 and D
otherwise, and Cþ assigned for Pc*
s R 10 and
C otherwise. For the initial conditions given
below, the rightmost boundary between DþC
and DþCþ is given by the line segment cd; this
boundary shifts to the line segment ab when the
initial conditions Dd*(0) and Pc*(0) are increased
to 1 and 0.1, respectively (other initial conditions
fixed as given below). This change in initial condi-
tions also shifts the boundary between DC and
DCþ from line segments ce to bf. Equations 3
and 4 and Eqs. A11–A14 in the Appendix are
used in the simulations. Parameter values: k1
0 ¼
0.01, k2
0 ¼ 1, k30 ¼ 0.01, k40 ¼ 100, k4b0 ¼ 0.1,
k5
0 ¼ 0.1, k5b0 ¼ 1, k60 ¼ 2.1, k6b0 ¼ 1.6, k70 ¼ 3,
k7b
0 ¼ 5, k80 ¼ 10, k8b0 ¼ 20, k90 ¼ 1, k100 ¼ 1,
k10b
0 ¼ 1, k110 ¼ 0.1, s20 ¼ 1, ss0 ¼ 0.01, sc0 ¼
0.01, sa
0 ¼ 0.01, d0 ¼ 0.5, dms0 ¼ 2.5, dmd0 ¼ 2.5,
dmc
0 ¼ 2.5, and dma0 ¼ 2.5. Initial conditions:
m*(0) ¼ 0.1, p*(0) ¼ 0.05, Ds*(0) ¼ 1.1,
Dd*(0) ¼ 0.0001, Pc*(0) ¼ 0.001, and Pa*(0) ¼
0.0001.
Myc-p53 Control System 2089The significance of the dysregulation of this feedback
loop in cancer has been suggested by Rochlitz et al. (1)
more than 15 years ago. Here, we have demonstrated by
kinetic modeling that decreasing the strength of this negative
loop (by varying the values of the associated control param-
eters) leads to an increase in the peak value and/or steady
state of Myc (Fig. 3, b and c). This could arise, for example,
through mutation or inactivation of p53 that decreases its
ability to inhibit Myc. In addition to the negative feedback
loop, a direct or indirect pathway from Myc to p53 that
has a net effect of inhibiting p53 would create a positive
feedback loop that can cause large increases in Myc.
In terms of cancer development, the consequences of
increasing Myc levels can be predicted if we can locate
the cancer zone, CZ (18)—the range of Myc associated
with increased probability of cancer as depicted in Fig. 1 b.
The residence time and Myc levels (ACZ in Fig. 3 a) within
the CZ are predicted to be key factors for inducing down-
stream tumorigenic events. An experimental surrogate for
the magnitude of ACZ would be useful for predicting suscep-
tibility to cancer.
We view the ARF/MDM2 and PTEN/AKT pathways
as perturbations of the core Myc-p53 control system and,
aided by kinetic modeling, have explained published reports
on the effects of deletions of p53, PTEN, ARF, and overex-
pression of MDM2, on the phenotypes of mouse neural stem
cells—thus, suggesting potential mechanisms for glioma-
genesis. Furthermore, the qualitative modular network
(Fig. 1 a) that models the coordination of cell proliferation
and differentiation by the Myc-p53 control system predicts
six cellular phenotypes (Table 1) and that two of these are
probable cancer precursors (DþCþ and DCþ in Fig. 7).
Finally, we demonstrated how our model generates these
cellular phenotypes by the combined effects of two
signaling pathways, one that signals to Myc and the other
to a transcription factor that induces differentiation.APPENDIX
Dimensionless forms of Eqs. 10–14
dm
dt
¼ 1
k01 þ s02p
 m; (A1)
0 dp

0  0  1 d
dt
¼ k2m þ k14q þ k03 þ s01m þ s04w
 p ; (A2)
00 dw

0  1 d
dt
¼ k16p þ k017 þ s03q þ s05v
 w ; (A3)
000 dq

0 0  d
dt
¼ ε3 þ k13p  q ; (A4)0000 dv

0 k
0
15m

d
dt
¼ ε5 þ k019 þ p
 v ; (A5)
where
t ¼ dmt; m ¼ m
s1
; p ¼ p
s2
;
q ¼ q
s3
; w ¼ w
s4
; v ¼ v
s5
;
(A6)
d0 ¼ dm
dp
; d00 ¼ dm
dw
; d000 ¼ dm
dq
;
d0000 ¼ dm
dv
; ε03 ¼
ε3
dq
; ε05 ¼
ε5
dv
;
(A7)
s01 ¼
dp
ε2
s1; s
0
2 ¼
dm
ε1
s2; s
0
3 ¼
dw
ε4
s3;
s04 ¼
dpk12
ε2
s4; s
0
5 ¼
dwk18
ε4
s5;
(A8)
k01 ¼
dm
ε1
k1; k
0
2 ¼
s1
s2dp
k2;
k03 ¼
dp
ε2
k3; k
0
13 ¼
s2
dqs3
k13;
(A9)
k014 ¼
s3
s2dp
k14; k
0
15 ¼
s1
s2s5dv
k15;
k016 ¼
s2
dws4
k16; k
0
17 ¼
dw
ε4
k17; k
0
19 ¼
k19
s2
:
(A10)
Dimensionless forms of Eqs. 15–18
d0ms
dDs
dt
¼ s0s þ

k06 þ k06bm

D4s
1þ D4s þ k05p þ k05bDd
 Ds ; (A11)
d0md
dDd
dt
¼ s0d þ

k07 þ k07bp

D4d
1þ D4d þ k04m þ k04bDs
 Dd; (A12)
d0mc
dPc
dt
¼ s0c þ

k08 þ k08bm

P2c
1þ P2c þ k011p
 Pc ; (A13)
d0ma
dPa
dt
¼ s0a þ

k010 þ k010bm þ k09p

P2a
1þ P2a
 Pa; (A14)
whereBiophysical Journal 101(9) 2082–2091
2090 Aguda et al.t ¼ dmt; m ¼ m
s1
; p ¼ p
s2
;
Ds ¼
Ds
qs
; Dd ¼
Dd
qd
; Pc ¼
Pc
qc
; Pa ¼
Pa
qa
;
(A15)
0 dm 0 s1 0 dpk1 ¼ ε1 k1; k2 ¼ s2dp k2; k3 ¼ ε2 k3;
k05 ¼
s2
q4s
k5; k
0
6 ¼
1
qsds
k6; k
0
6b ¼
S1
qsds
k6b;
(A16)
0 qd 0 1 0 s2k5b ¼
q4s
k5; k7 ¼ qddd k7; k7b ¼ qddd k7b;
k04 ¼
s1
q4d
k4; k
0
4b ¼
qs
q4d
k4b; k
0
8 ¼
1
qcdc
k8;
(A17)
0 s1 0 s2k8b ¼ qcdc k8b; k11 ¼ q2c
k11;
k010 ¼
1
qada
k10; k
0
10b ¼
s1
qada
k10b; k
0
9 ¼
s2
qada
k9;
(A18)
dp 0 dm 0 εss01 ¼ ε2 s1; s2 ¼ ε1 s2; ss ¼ qsds ss;
s0d ¼
εd
qddd
sd; s
0
c ¼
εc
qcdc
sc; s
0
a ¼
εa
qada
sa;
(A19)
0 dm 0 dm 0 dmd ¼
dp
; dms ¼ ds ; dmd ¼ dd ;
d0mc ¼
dm
dc
; d0ma ¼
dm
da
:
(A20)
SUPPORTING MATERIAL
Two additional parts with one table and supporting equations are available at
http://www.biophysj.org/biophysj/supplemental/S0006-3495(11)01183-0.
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